Gladstone launches the new Institute of Data Science and Biotechnology
Scientists examine the fastest changing regions in the human genome to learn how our species evolved
Scientists receive $8.5M in funding to accelerate progress towards a cure for HIV
An unexpected collaboration leads to the discovery of an early predictor of IBD
Katherine Pollard, PhD, director of the convergence science initiative at the Gladstone Institutes, has been selected as a Chan Zuckerberg Investigator.
Katherine Pollard’s expertise, success, and vision fueled her promotion to director of Gladstone’s Convergence Zone.
Researchers at the Gladstone Institutes and UCSF have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.
Researchers at Maastricht University and the Gladstone Institutes tackled the challenge of improving the integration of disparate sources and types of data and advance scientists’ understanding of disease.
The White House invited Katherine Pollard to join the National Microbiome Initiative as a leader in the field of bioinformatics.
In their pursuit of cures for debilitating diseases, Gladstone scientists are approaching precision medicine from new angles, researching the microbiome and protein networks that are critical for human biology.
Katherine Pollard’s lab has invented a novel way to read and interpret the human genome. This technology opens the door to identifying drug targets that could treat genetic diseases.
Katherine Pollard shares science on big data and high-performance computing with an audience at Google as part of the Gladstone Open Classroom Talks series.
The most influential “organ” in the human body is made up of foreign cells—six pounds worth of microorganisms. Katherine Pollard studies the human microbiome to learn how it influences health and disease.
Gladstone has received funding from the National Institutes of Health to continue and expand two exciting projects in cardiovascular research. The funding, totaling more than $6.8 million, supports two teams of scientists and their research on congenital heart disease.
Collaborations have been key to Gladstone’s scientific success since its founding, and its community believes that the biggest challenges in science are better met by bringing together researchers with diverse backgrounds.